Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Zhibao Technology Raises $154.7 Million Through Equity PIPE Financing, with 2,380 BTC Credited Directly

Nasdaq-listed Chinese embedded digital insurance technology company Zh保科技 (ZBAO) announced on August 19 that it had completed a $154.7 million PIPE (private investment in public equity) financing. The financing used a rare structure in which cryptocurrency was provided directly as consideration: a group of non-U.S. investors paid with 2,380 Bitcoin, all of which was deposited into Zh保科技’s official wallet, rather than first raising fiat currency and then purchasing Bitcoin on the market. PIPE Fin
BTC-0.20%
MSTR0.12%
MarketWhisper·08-20 01:38
智保科技股票PIPE融資1.547億美元

ING Bank Forecasts Fed Rate Hold Through 2027 Despite Hawkish FOMC Minutes

ING Bank forecasts the Federal Reserve will hold interest rates steady through 2027 despite hawkish signals in July Federal Open Market Committee (FOMC) minutes, according to a report issued on the 19th (local time) by Jamie Knightley, ING's Chief International Economist. The assessment follows July
ING0.34%
LucasBennett·08-20 01:32
ING Bank Forecasts Fed Rate Hold Through 2027 Despite Hawkish FOMC Minutes

Moderna stock surges 176%; mRNA cancer vaccine Phase 3 meets its endpoint

Merck and Moderna (MRNA) issued a joint announcement on August 19 stating that their investigational personalized mRNA neoantigen therapy, intismeran (V940), in combination with the anti-PD-1 therapy KEYTRUDA, achieved positive results in the Phase 3 INTerpath-001 clinical trial. MRNA closed up 176.97% at $174.38. Key Data from the INTerpath-001 Trial According to the joint announcement from Merck and Moderna, the Phase 3 INTerpath-001 clinical trial achieved the following four results in a pres
MRNA-7.79%
MRK1.71%
BNTX-1.90%
MarketWhisper·08-20 01:31
Moderna mRNA癌症疫苗Phase 3達標